# Metabolic Consequences of Gastrointestinal Surgery

> **NCT02836353** · NA · TERMINATED · sponsor: **Cambridge University Hospitals NHS Foundation Trust** · enrollment: 81 (actual)

## Conditions studied

- Gastrectomy
- Oesophagectomy
- Dumping Syndrome
- Hypoglycaemia

## Interventions

- **DRUG:** Somatostatin
- **DRUG:** Rifaximin

## Key facts

- **NCT ID:** NCT02836353
- **Lead sponsor:** Cambridge University Hospitals NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-01
- **Primary completion:** 2019-03-11
- **Final completion:** 2019-03-11
- **Target enrollment:** 81 (ACTUAL)
- **Why stopped:** Reached scientific goals, further recruitment would not further advance the findings of study.
- **Last updated:** 2019-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02836353

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02836353, "Metabolic Consequences of Gastrointestinal Surgery". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02836353. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*